tetano
Editor, Senior Moderator
Cell Rep Methods
. 2022 Feb 24;100181.
doi: 10.1016/j.crmeth.2022.100181. Online ahead of print.
Development of a hybrid alphavirus-SARS-CoV-2 pseudovirion for rapid quantification of neutralization antibodies and antiviral drugs
Brian Hetrick[SUP] 1 [/SUP], Linda D Chilin[SUP] 1 [/SUP], Sijia He[SUP] 1 [/SUP], Deemah Dabbagh[SUP] 1 [/SUP], Farhang Alem[SUP] 1 [/SUP], Aarthi Narayanan[SUP] 1 [/SUP], Alessandra Luchini[SUP] 2 [/SUP], Tuanjie Li[SUP] 3 [/SUP], Xuefeng Liu[SUP] 3 4 [/SUP], Joshua Copeland[SUP] 5 [/SUP], Angela Pak[SUP] 5 [/SUP], Tshaka Cunningham[SUP] 5 [/SUP], Lance Liotta[SUP] 2 [/SUP], Emanuel F Petricoin[SUP] 2 [/SUP], Ali Andalibi[SUP] 1 [/SUP], Yuntao Wu[SUP] 1 [/SUP]
Affiliations
Abstract
SARS-CoV-2 spike protein (S) pseudotyped viruses are commonly used for quantifying antiviral drugs and neutralizing antibodies. Here we describe the development of a hybrid alphavirus-SARS-CoV-2 pseudovirion (Ha-CoV-2), which is a non-replicating SARS-CoV-2 virus-like particle composed of viral structural proteins (S, M, N, and E) and a RNA genome derived from a fast expressing alphaviral vector. We validated Ha-CoV-2 for rapid quantification of neutralization antibodies, antiviral drugs, and viral variants (e.g. delta). In addition, as a proof-of-concept, we used Ha-CoV-2 to quantified the neutralizing antibodies from an infected and vaccinated individual, and found that the one dose vaccination with Moderna mRNA-1273 has greatly increased the anti-serum titer for approximately 6 fold. The post-vaccination serum can neutralize all 9 variants tested. These results demonstrate that Ha-CoV-2 can be used as a robust platform for rapid quantification of neutralizing antibodies against SARS-CoV-2 and its emerging variants.
Keywords: COVID-19; Ha-CoV-2; SARS-CoV-2; SARS-CoV-2 variants; alphavirus; antiviral drug; coronavirus; lentivirus; mRNA vaccine; neutralizing antibody; pseudovirus.
. 2022 Feb 24;100181.
doi: 10.1016/j.crmeth.2022.100181. Online ahead of print.
Development of a hybrid alphavirus-SARS-CoV-2 pseudovirion for rapid quantification of neutralization antibodies and antiviral drugs
Brian Hetrick[SUP] 1 [/SUP], Linda D Chilin[SUP] 1 [/SUP], Sijia He[SUP] 1 [/SUP], Deemah Dabbagh[SUP] 1 [/SUP], Farhang Alem[SUP] 1 [/SUP], Aarthi Narayanan[SUP] 1 [/SUP], Alessandra Luchini[SUP] 2 [/SUP], Tuanjie Li[SUP] 3 [/SUP], Xuefeng Liu[SUP] 3 4 [/SUP], Joshua Copeland[SUP] 5 [/SUP], Angela Pak[SUP] 5 [/SUP], Tshaka Cunningham[SUP] 5 [/SUP], Lance Liotta[SUP] 2 [/SUP], Emanuel F Petricoin[SUP] 2 [/SUP], Ali Andalibi[SUP] 1 [/SUP], Yuntao Wu[SUP] 1 [/SUP]
Affiliations
- PMID: 35229082
- PMCID: PMC8866097
- DOI: 10.1016/j.crmeth.2022.100181
Abstract
SARS-CoV-2 spike protein (S) pseudotyped viruses are commonly used for quantifying antiviral drugs and neutralizing antibodies. Here we describe the development of a hybrid alphavirus-SARS-CoV-2 pseudovirion (Ha-CoV-2), which is a non-replicating SARS-CoV-2 virus-like particle composed of viral structural proteins (S, M, N, and E) and a RNA genome derived from a fast expressing alphaviral vector. We validated Ha-CoV-2 for rapid quantification of neutralization antibodies, antiviral drugs, and viral variants (e.g. delta). In addition, as a proof-of-concept, we used Ha-CoV-2 to quantified the neutralizing antibodies from an infected and vaccinated individual, and found that the one dose vaccination with Moderna mRNA-1273 has greatly increased the anti-serum titer for approximately 6 fold. The post-vaccination serum can neutralize all 9 variants tested. These results demonstrate that Ha-CoV-2 can be used as a robust platform for rapid quantification of neutralizing antibodies against SARS-CoV-2 and its emerging variants.
Keywords: COVID-19; Ha-CoV-2; SARS-CoV-2; SARS-CoV-2 variants; alphavirus; antiviral drug; coronavirus; lentivirus; mRNA vaccine; neutralizing antibody; pseudovirus.